GlassScriptPhysician profile
Mahmoud Rayes
NPI 1942464961
$53,464.92
in general payments reported to CMS, 2019-2025
22 companies · $10K in 2025
The $10K reported for 2025 was more than what 97% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $609 · 2021: $1,195 · 2022: $3,972 · 2023: $11K · 2024: $26K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $7,425 · Food and Beverage: $5,062 · Travel and Lodging: $2,592 · Entertainment: $15.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,175.00 |
| Consulting Fee | $7,425.00 |
| Food and Beverage | $5,061.58 |
| Travel and Lodging | $2,591.91 |
| Entertainment | $15.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $48,861.65 | 2021-2025 | Pipeline, Solitaire X, Axium Primetm |
| Stryker Corporation | $1,376.32 | 2019-2024 | Trevo, Surpass Evolve |
| Qapel Medical INC | $870.82 | 2024-2025 | |
| Penumbra, INC. | $458.52 | 2020-2022 | |
| Viz.Ai, INC. | $354.10 | 2022 | |
| Medtronic USA, INC. | $297.01 | 2020 | |
| Balt USA, LLC | $160.40 | 2021-2024 | Ballast 088 Long Sheath |
| Microvention, INC. | $144.22 | 2019-2025 | Web Aneurysm Embolization System |
| Imperative Care, INC | $144.20 | 2022 | |
| Depuy Synthes Sales INC. | $119.73 | 2019 | |
| Chiesi USA, INC. | $116.53 | 2023 | Cleviprex |
| Astrazeneca Pharmaceuticals LP | $113.43 | 2022 | |
| Portola Pharmaceuticals, LLC | $107.26 | 2019 | |
| Jazz Pharmaceuticals INC. | $100.03 | 2022 | |
| Btg International INC. | $60.41 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaneka Medical America LLC | $58.99 | 2023-2024 | |
| Pfizer INC. | $34.54 | 2022-2023 | |
| Genentech USA, INC. | $24.31 | 2025 | Tnkase |
| Terumo Medical Corporation | $23.20 | 2025 | Tr Band |
| Abbott Laboratories | $21.49 | 2022 | |
| Cordis US Corp. | $17.76 | 2025 | Precise Pro Rx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Rayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.